[Amiodarone and secondary prevention. The EMIAT study].
The EMIAT is a randomized, double-blind trial versus placebo, designed to evaluate the efficacy of amiodarone in the prevention of total mortality in patients with left ventricular ejection fraction of under 40% after myocardial infarction. This multicenter European trial initiated by SANOFI Research in association with the Arrhythmia Working Group of the European Society of Cardiology, is part of a larger program of evaluation (3,400 patients) of the benefit-risk ratio of the use of amiodarone for secondary prevention in high risk patients.
Munoz
A
A
Centre de coordination EMIAT, Sanofi Recherche, Montpellier.
D000638:Amiodarone / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D004311:Double-Blind Method; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D013318:Stroke Volume
D000638:Amiodarone
Amiodarone et prévention secondaire. L'essai EMIAT.